What is Calithera Biosciences Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Calithera Biosciences's annualizedGross Profit for the quarter that ended in Dec. 2022 was $0.00 Mil.
Calithera Biosciences's average Total Assets over the quarter that ended in Dec. 2022 was $32.88 Mil. Therefore, Calithera Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 0.00%.
Calithera Biosciences Gross-Profit-to-Asset % Historical Data
The historical data trend for Calithera Biosciences's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Calithera Biosciences's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Calithera Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calithera Biosciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Calithera Biosciences's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2022) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Calithera Biosciences Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Calithera Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Calithera Biosciences (Calithera Biosciences) Business Description
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CALA has been successfully added to your 